Overview

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
0
Participant gender:
All
Summary
Evaluation of the intraocular pressure (IOP) lowering effect of two iStent inject devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Glaukos Corporation
Treatments:
Travoprost
Criteria
Inclusion Criteria:

- Phakic study eye

- IOP ≥ 21 mmHg and ≤ 40 mmHg at the screening visit (subjects with OHT require a second
screening IOP measurement

Exclusion Criteria:

- Aphakic or pseudophakic eyes (AC-IOLs or PC-IOLs)

- Previous usage of topical prostaglandin analogues or prior medical therapy for
glaucoma